Esperion Therapeutics Inc. has nominated ESP-2001 as a preclinical development candidate for the treatment of primary ...
Zacks Investment Research on MSN
Will Space Unit's Performance Weigh on Northrop's Q3 Earnings?
Northrop Grumman Corporation NOC is scheduled to report third-quarter 2025 results on Oct. 21, before market open. The ...
Zacks Investment Research on MSN
Will Unfavorable Charges & Taxes Hurt Lockheed's Q3 Earnings?
Lockheed Martin Corporation LMT is scheduled to release third-quarter 2025 results on Oct. 21, before market open. The ...
Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary ...
The ABE 1.01 is ready for use in surveillance operations, however, the aim is to eventually use it for lethal capabilities, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback